Judge Orders FDA to Reconsider 3 Mifepristone Curbs as Pills Account for Nearly Two-Thirds of US Abortions
Updated
Updated · The Guardian · Jul 24
Judge Orders FDA to Reconsider 3 Mifepristone Curbs as Pills Account for Nearly Two-Thirds of US Abortions
3 articles · Updated · The Guardian · Jul 24
Summary
US District Judge Robert Ballou ruled Friday that FDA restrictions on mifepristone were arbitrary and capricious, ordering the agency to reexamine rules abortion providers say block access.
Three challenged requirements include special registration and certification for prescribers and pharmacies, plus patient paperwork the plaintiffs called duplicative, inaccurate and confusing.
Ballou said prior FDA reviews had consistently found mifepristone safe and effective, backing a lawsuit filed in May 2023 by providers in Virginia, Kansas and Montana.
The order lands as the FDA conducts a broader abortion-pill review and as a separate Fifth Circuit case could restore tighter limits on mail-order mifepristone and pharmacy prescribing.
Mifepristone now accounts for nearly two-thirds of US abortions, making the fight over dispensing rules central to access as patients increasingly travel from ban states for care.
What specific medical evidence will the FDA use to determine if the current prescription restrictions are arbitrary?
How will conflicting federal court rulings impact the nationwide availability of telehealth and mail-order prescriptions?
Could emerging state shield laws fully protect medical providers who distribute restricted medications across state lines?
Supreme Court, FDA, and the States: The 2026 Fight Over Mail-Order Abortion Pills and the Future of Reproductive Healthcare
Overview
After the Supreme Court overturned Roe v. Wade in 2022, states gained the power to regulate abortion, leading to a surge in mail-order prescriptions and telemedicine for abortion medications. In response, Louisiana sued the FDA in 2025 to restrict access to mifepristone, triggering a series of legal battles. The Trump administration paused the case for an FDA safety review, but the 5th Circuit Court reinstated strict in-person requirements. Emergency appeals reached the Supreme Court, which temporarily blocked these restrictions, keeping mifepristone accessible nationwide. Meanwhile, blue states enacted shield laws to protect providers, while the pharmaceutical industry warned that judicial interference could disrupt drug regulation across the country.